Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol. 2014;20:1192–1210.
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148:344–354.
   PubMed Web of Science ®Google Scholar
• Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987–995.
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C. Paradoxical effects of anti-TNF-alpha agents in inflammatory diseases. Expert Rev Clin Immunol. 2014;10:159–169.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051–1063.
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199–209.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Gionchetti P, Daperno M, et al. Expert consensus paper on the use of vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease. Dig Liver Dis. 2016;48:360–370.
   PubMedGoogle Scholar
• Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol. 2016;29:243–248.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Côté-Daigneault J, Bouin M, Lahaie R, et al. Biologics in inflammatory bowel disease: what are the data. United Eur Gastroenterol J. 2015;3:419–428.
   PubMed Web of Science ®Google Scholar
• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–789.
   PubMedGoogle Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–999.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–1141.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Gee K, Guzzo C, Mat C, et al. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8:40–52.
   PubMedGoogle Scholar
• Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA. 1996;93:14002–14007.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–146.
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL- 23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–5708.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910–1914.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang H, Kugathasan S, et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn disease. Am J Hum Genet. 2009;84:399–405.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218–1222.
   PubMed Web of Science ®Google Scholar
• Vanden Eijnden S, Goriely S, De Wit D, et al. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol. 2005;35:469–475.
   PubMed Web of Science ®Google Scholar
• Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208:1127–1133.
   PubMed Web of Science ®Google Scholar
• Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the differentiation and expansion of IL-17A and IL-22-producing human gammadelta T cells. J Immunol. 2010;184:7268–7280.
   PubMed Web of Science ®Google Scholar
• Van de Wetering D, De Paus RA, Van Dissel JT, et al. IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NKlike T cell function differentially from IL-12. Int Immunol. 2009;21:45–53.
   Web of Science ®Google Scholar
• Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12(1):9–15.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yadav PK, Xu X, et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol. 2011;89(4):597–606.
   PubMed Web of Science ®Google Scholar
• Kleinschek MA, Muller U, Brodie SJ, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol. 2006;176:1098–1106.
   PubMed Web of Science ®Google Scholar
• Lieberman LA, Cardillo F, Owyang AM, et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol. 2004;173:1887–1893.
   PubMed Web of Science ®Google Scholar
• Rudner XL, Happel KI, Young EA, et al. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun. 2007;75:3055–3061.
   PubMed Web of Science ®Google Scholar
• Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 2014;25:415–421.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab in inducing endoscopic healing in patients with Crohn’s disease. Gastroenterology. 2018 Jun 14 pii;S0016–5085(18):34655–34659.
   Google Scholar
• Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65–77.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease. Gastroenterology. 2018;154:1660–1671.
   PubMed Web of Science ®Google Scholar
• Sands B, Gasink C, Jacobstein D, et al. Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn’s disease patients: results from the IM-UNITI maintenance study [abstract]. Am J Gastroenterol. 2016;111:S302–3.
   Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R et al. Safety and efficacy of ustekinumab induction therapy in patients with moderate to severe ulcerative colitis: results from the Phase 3 UNIFI study [abstract]. Presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting; Philadelphia, Pennsylvania; 2018 Oct 5–10.
   Google Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
   PubMed Web of Science ®Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232–1243.
   PubMed Web of Science ®Google Scholar
• Greenup AJ, Rosenfeld G, Bressler B. Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience. Scand J Gastroenterol. 2017;52:1354–1359.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–250.
   PubMed Web of Science ®Google Scholar
• Harris KA, Horst S, Gadani A, et al. Patients with refractory Crohn’s disease successfully treated with ustekinumab. Inflamm Bowel Dis. 2016;22:397–401.
   PubMed Web of Science ®Google Scholar
• Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–1669.
   PubMed Web of Science ®Google Scholar
• Battat R, Kopylov U, Bessissow T, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15:1427–1434.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148–1158.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14:706–714.
   PubMed Web of Science ®Google Scholar
• Loftus JE, Augustin M, Bissonnette R, et al. Prevalence of inflammatory bowel disease amongst patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR registry [poster]. In: 11th Congress of ECCO 2016 - European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands; 2016. p. P626.
   Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al. PHOENIX 1 investigators. long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27:1535–1545.
   PubMed Web of Science ®Google Scholar
• Langley RG, Lebwohl M, Krueger GG, et al. PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172:1371–1383.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Griffiths CE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (PartI of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66:731–741.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66:742–751.
   PubMed Web of Science ®Google Scholar
• Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17:80.
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–35.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41:974–980.
   PubMed Web of Science ®Google Scholar
• Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: A phase 2a study. Gastroenterology. 2017;153:77–86.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389:1699–1709.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panés J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 Jul 25;3:671–680. pii: S2468-1253(18)30233-4.
   Web of Science ®Google Scholar
• Visvanathan S, Baum P, Salas A, et al. Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn’s disease: results from a randomised phase II biopsy substudy. J Crohns Colitis. 2018 Jul 19 Epub ahead of print. DOI:10.1093/ecco-jcc/jjy099.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of anti-interleukin-23 therapy with mirikizumab (LY3074828) in patients with moderate-to-severe ulcerative colitis in a phase 2 study. Gastroenterology. 2018;154:S-1360-S-1361.
   Web of Science ®Google Scholar
• Ryan C, Thrash B, Warren RB, et al. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther. 2010;10:587–604.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar